IL-23A/IL-23 P19 Antibody (risankizumab) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28777H
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
HRP
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # risankizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IL-23A/IL-23 P19 Antibody (risankizumab) [HRP]
Immunogen
IL-23a
Reactivity Notes
Predicted species reactivity: Cynomolgus
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for IL-23A/IL-23 P19 Antibody (risankizumab) [HRP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IL-23
Long Name
Interleukin 23
Alternate Names
IL-23 p19/IL-12 p40, IL-23p19/IL-12p40, IL23, SGRF
Gene Symbol
IL23A
Additional IL-23 Products
Product Documents for IL-23A/IL-23 P19 Antibody (risankizumab) [HRP]
Product Specific Notices for IL-23A/IL-23 P19 Antibody (risankizumab) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...